CD276 and non-small cell lung carcinoma: Therefore, we firstly investigated EGFR/B7H3 co-expression in a large NSCLC cohort (n = 222), and found high positivity rates across key subtypes: 75.9% in untreated LUSC, 55.0% in EGFR/ALK/ROS1 wild-type LUAD, and 53.3% in EGFR-TKI-resistant LUAD.